Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?

@article{Bisceglie2015RecentUF,
  title={Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?},
  author={Adrian M Di Bisceglie and A S Lok and Paul Martin and Norah A. Terrault and Robert P. Perrillo and Jay H. Hoofnagle},
  journal={Hepatology},
  year={2015},
  volume={61 2},
  pages={703-11}
}
UNLABELLED Reactivation of hepatitis B in the context of immunosuppressive therapy may be severe and potentially fatal. The US Food and Drug Administration has recently drawn attention to the potentially fatal risk of hepatitis B reactivation in patients receiving the anti-CD20 agents ofatumumab or rituximab. This action focuses attention on the broader issue of hepatitis B virus reactivation, which may occur with a wide variety of immunosuppressive therapies in benign or malignant disease… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 29 times over the past 90 days. VIEW TWEETS
48 Citations
30 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

and Drug Administration

  • US Foo
  • Boxed warning and new recommendations to decrease…
  • 2013
1 Excerpt

Hepatitis B virus ( HBV ) reactivation in patients receiving tumor necrosis factor ( TNF ) – targeted therapy

  • JH Hoofnagle, GL Davis, SC Pappas, RG Hanson, M Peters, MI Avigan
  • Medicine ( Baltimore )
  • 2011

Similar Papers

Loading similar papers…